hlhma
thought
multisystem
inflammatori
disord
result
proinflammatori
cytokin
storm
excess
activ
lymphocyt
macrophag
hemophagocyt
syndrom
divid
primari
secondari
form
primari
case
rare
live
birth
commonli
present
first
year
life
often
trigger
infect
includ
famili
primari
form
hemophagocyt
lymphohistiocytosi
fhlh
specif
genet
homozyg
compound
heterozyg
lossoffunct
mutat
perforinmedi
cytolyt
pathway
protein
eg
employ
cell
natur
killer
nk
cell
children
certain
immunodefici
syndrom
syndrom
type
ii
hermanskypudlak
syndrom
type
ii
griscelli
syndrom
associ
genet
defect
cytolysi
also
risk
develop
fhlh
specif
xlink
immunodefici
signalinglymphocyticactivationmoleculeassoci
protein
sap
xlink
inhibitor
apoptosi
xiap
defici
also
associ
epsteinbarr
viru
ebv
trigger
hlh
acquir
secondari
form
hlh
shlh
usual
associ
condit
caus
chronic
immun
dysregul
rheumatolog
diseas
eg
system
juvenil
idiopath
arthriti
sjia
system
lupu
erythematosu
sle
certain
malign
eg
leukemia
lymphoma
infecti
agent
particularli
ebv
herpesviru
famili
member
may
shlh
trigger
although
identifi
infect
alway
present
addit
shlh
macrophag
activ
syndrom
ma
patient
found
possess
heterozyg
domin
neg
mutat
known
fhlh
gene
thu
investig
consid
ma
shlh
fhlh
lie
spectrum
diseas
clinic
set
distinct
primari
secondari
form
hlh
less
clear
even
consid
artifici
initi
use
differenti
primari
fatal
infantil
present
secondari
form
consid
present
later
life
better
prognos
howev
known
primari
genet
form
present
later
life
even
adulthood
furthermor
studi
primari
hlh
case
found
recogn
genet
mutat
moreov
primari
secondari
hlh
known
precipit
infect
final
mention
previous
mani
patient
shlh
heterozyg
mutat
known
fhlhassoci
gene
thu
blur
distinct
fhlh
shlh
regardless
terminolog
individu
patient
need
treat
appropri
present
clinician
would
agre
clearcut
infantil
case
fhlh
need
bone
marrow
transplant
typic
preced
aggress
chemotherapeut
regimen
includ
etoposid
corticosteroid
addit
identifi
infecti
trigger
also
treat
appropri
children
adult
hlh
appropri
treatment
remain
unclear
etoposid
quit
toxic
often
lead
pancytopenia
increas
risk
secondari
sepsi
well
increas
risk
secondari
malign
novel
approach
anecdot
report
dampen
overli
exuber
immun
respons
control
cytokin
storm
associ
multiorgan
dysfunct
notabl
target
specif
proinflammatori
cytokin
eg
interferongamma
seem
promis
lack
toxic
associ
tradit
chemotherapeut
approach
despit
advanc
current
treatment
protocol
cure
rate
hlh
low
untreat
case
fhlh
median
surviv
less
month
diagnosi
nationwid
registri
pediatr
patient
hlh
korea
overal
surviv
rate
famili
group
presum
secondari
group
prognosi
case
shlh
vari
depend
underli
etiolog
exampl
mortal
rate
report
lower
case
associ
rheumat
diseas
greater
associ
malign
median
overal
surviv
mashlh
develop
cytokin
storm
often
trigger
infecti
rheumatolog
oncolog
diseas
although
well
defin
proinflammatori
cytokin
associ
mashlh
like
includ
tumor
necrosi
factor
tnf
tabl
also
macrophag
colonystimul
factor
mcsf
granulocytemacrophag
colonystimul
factor
gmcsf
may
increas
furthermor
chemokin
report
increas
cytokin
chemokin
activ
immun
system
perpetu
ongo
cytokin
storm
arm
level
antiinflammatori
cytokin
protein
also
increas
might
suffici
termin
ongo
inflamm
mazodi
et
al
describ
discrep
increas
antagonist
lead
abnorm
high
level
free
similarli
natur
antagonist
receptor
antagonist
note
elev
mashlh
recombin
form
report
sever
group
effect
therapi
mashlh
cytokin
storm
syndrom
etiolog
cytokin
storm
entir
clear
sinc
fhlh
associ
biallel
defect
gene
product
involv
perforinmedi
cytolyt
pathway
use
nk
cell
lymphocyt
inabl
clear
antigen
stimulu
thu
turn
inflammatori
respons
hypothes
result
hypercytokinemia
recent
inabl
cell
nk
cell
lyse
antigenpres
cell
apc
via
perforinmedi
cytolyt
pathway
shown
prolong
fivefold
engag
time
lytic
lymphocyt
apc
prolong
interact
result
increas
level
proinflammatori
cytokin
shlh
case
singlecopi
mutat
perforin
pathway
gene
report
mutant
demonstr
act
complet
partial
dominantneg
mutant
result
shlh
older
children
adult
oldest
report
case
patient
one
heterozyg
mutat
identifi
two
unrel
shlh
patient
shown
act
partial
dominantneg
fashion
delay
cytolyt
granul
polar
immunolog
synaps
nk
cell
target
cell
also
associ
increas
product
mimick
situat
describ
homozyg
defect
perforin
granzym
b
moreov
increas
product
shown
decreas
cytolyt
activ
nk
cell
exacerb
lytic
defect
result
product
proinflammatori
cytokin
healthi
individu
exposur
cell
mani
intracellular
pathogen
normal
initi
inflammatori
cascad
frequent
lead
releas
cytokin
tnf
activ
macrophag
nk
cell
cytolyt
cell
nk
cytolyt
cell
releas
granul
contain
perforin
granzym
perforin
key
cytolyt
protein
caus
osmot
lysi
target
cell
also
necessari
uptak
granzym
target
cell
catalyz
cleavag
multipl
protein
substrat
includ
caspas
trigger
cell
apoptosi
genet
defect
describ
fhlh
involv
either
inadequ
level
perforin
improp
granul
exocytosi
lead
impair
apoptosi
target
cell
improp
remov
stimul
antigen
ultim
ongo
inflamm
howev
pathway
lack
cytolyt
pathway
gene
defect
lead
final
endpoint
hlh
ma
murin
model
ma
shown
repeat
stimul
tolllik
receptor
produc
ma
normal
genet
background
without
exogen
antigen
interestingli
ma
model
depend
aspect
diseas
howev
lymphocyt
requir
pathogenesi
hand
state
inflamm
may
also
reduc
lytic
capac
nk
cell
cell
result
cytokin
storm
due
frustrat
phagocytosi
illustr
studi
tcelldirect
immunotherapi
refractori
leukemia
result
cytokin
storm
maslik
present
aforement
pathway
led
propos
ma
due
combin
genet
predisposit
hyperinflammatori
state
reduc
cytolyt
function
put
action
trigger
eg
infect
cancer
immunodefici
autoimmun
autoinflamm
point
threshold
level
hypercytokinemia
reach
bodi
incap
balanc
cytokin
storm
antiinflammatori
product
other
believ
trigger
multiorgan
dysfunct
result
clinic
hlh
initi
symptom
hlhma
usual
nonspecif
cardin
featur
unremit
high
fever
howev
therapeut
target
proinflammatori
cytokin
eg
treat
underli
rheumat
diseas
often
result
ma
eg
sjia
make
fever
absolut
find
case
attribut
power
antipyret
effect
biolog
inhibitor
tnf
examin
mani
patient
hepatomegali
splenomegali
mashlh
patient
central
nervou
system
involv
rang
mild
confus
seizur
frank
coma
differ
form
rash
occur
often
erythemat
purpur
patient
progress
hepat
dysfunct
ultim
multiorgan
failur
diclik
featur
often
present
partli
explain
liver
dysfunct
fibrinogen
consumpt
thrombocytopenia
highlight
challeng
distinguish
microbi
sepsisinduc
dic
hlh
intens
care
unit
icu
despit
similar
two
condit
share
clinic
present
frequent
treat
differ
broad
spectrum
antibiot
sepsi
versu
immunosuppress
hlh
respect
hlh
diagnosi
exclus
infect
common
trigger
hlh
import
treat
infect
present
associ
cytokin
storm
hlh
mashlh
difficult
diagnos
especi
earli
stage
easili
misdiagnos
shock
multiorgan
dysfunct
due
sepsi
addit
ma
may
confus
underli
diseas
flare
case
sjia
ma
high
mortal
rate
children
sjia
sensit
diagnost
criteria
need
assist
earli
detect
allow
appropri
time
therapi
differ
diseas
associ
mashlh
differ
diagnost
classif
criteria
propos
year
slema
criteria
hscore
novel
criteria
ma
complic
sjia
tabl
criteria
diseas
specif
eg
sjia
sle
sensit
specif
wherea
other
encompass
potenti
hlhassoci
diagnos
tend
lower
sensit
overal
clinic
outsid
clinic
trial
due
fact
ma
resembl
fhlh
clinic
present
diagnost
guidelin
initi
use
diagnos
ma
guidelin
develop
diagnos
genet
homozygouscompound
heterozyg
case
fhlh
main
defici
regard
criteria
diagnos
ma
patient
sjia
due
underli
inflammatori
natur
sjia
versu
fhlh
activ
sjia
one
would
expect
elev
level
white
blood
cell
count
platelet
fibrinogen
part
inflammatori
process
accordingli
drop
level
could
still
normal
limit
regard
criteria
rais
suspicion
ma
also
underli
inflammatori
process
lead
elev
level
ferritin
therefor
cutoff
ferritin
ngml
guidelin
make
difficult
distinguish
ma
complic
sjia
sjia
flare
ad
shortcom
guidelin
overal
lack
avail
time
result
certain
criteria
nk
cell
activ
level
mani
center
eventu
preliminari
diagnost
criteria
introduc
sjiama
compar
sjia
flare
yield
better
result
identifi
ma
among
sjia
patient
compar
diagnost
guidelin
howev
new
criteria
shortcom
studi
led
criteria
develop
lack
import
laboratori
paramet
includ
import
ma
marker
ferritin
lactat
dehydrogenas
triglycerid
moreov
base
rel
small
sampl
patient
valid
shortcom
impetu
develop
new
sjiaspecif
ma
criteria
defici
previou
guidelin
push
develop
accur
criteria
sjiama
recent
novel
classif
criteria
introduc
result
intern
collabor
effort
combin
expert
consensu
evid
compil
medic
literatur
analysi
real
patient
develop
criteria
conduct
auspic
european
leagu
rheumat
american
colleg
rheumatolog
paediatr
rheumatolog
intern
trial
organ
base
common
consensu
clinic
criteria
ma
often
delay
andor
difficult
distinguish
underli
diseas
flare
sjiama
criteria
base
primarili
laboratori
paramet
fever
clinic
criterion
criteria
rel
simpl
yet
prove
highli
sensit
specif
howev
criteria
ideal
set
children
sjia
activ
treat
blockad
ultim
simpl
criteria
necessarili
diseas
specif
maintain
high
sensit
specif
establish
mashlh
diagnosi
need
childhood
sle
csle
case
complic
ma
report
increas
frequenc
recent
year
sle
diseas
flare
often
result
pancytopenia
diagnost
criteria
ma
set
sle
complic
accordingli
suggest
cslema
may
underrecogn
preliminari
guidelin
slema
propos
studi
conduct
base
multin
survey
data
analyz
patient
cslema
patient
evid
macrophag
hemophagocytosi
bone
marrow
aspir
consid
definit
ma
consid
probabl
ma
sensit
specif
area
receiv
oper
characterist
curv
variou
clinic
laboratori
paramet
compar
sle
patient
ma
versu
patient
activ
juvenil
sle
without
ma
best
diagnost
perform
obtain
use
simultan
presenc
one
clinic
criteria
two
laboratori
criteria
sensit
specif
tabl
demonstr
macrophag
hemophagocytosi
bone
marrow
aspir
consid
necessari
confirm
doubt
case
result
led
practic
recommend
clinic
set
ma
suspect
patient
csle
present
unexplain
fever
cytopenia
associ
hyperferritinemia
criteria
preliminari
diagnost
guidelin
sjiama
test
studi
found
inaccur
detect
cslema
interestingli
twothird
patient
cslema
develop
within
month
sle
diagnosi
frequenc
icu
admiss
mortal
rate
fardet
et
al
develop
partial
valid
diagnost
score
broader
categori
reactiv
hemophagocyt
syndrom
hs
call
hscore
use
estim
individu
risk
reactiv
hemophagocyt
syndrom
hlh
score
creat
test
use
multicent
retrospect
cohort
patient
scrutin
explanatori
variabl
issu
previou
delphi
survey
involv
hlh
expert
countri
show
posit
associ
variabl
hlh
diagnosi
multivari
logist
regress
use
assess
independ
contribut
outcom
follow
calcul
variabl
threshold
valu
coeffici
result
multipl
logist
regress
analysi
use
assign
score
point
one
perform
score
assess
use
development
valid
data
set
hscore
reveal
excel
diagnost
perform
discrimin
abil
development
valid
data
set
probabl
hlh
rang
hscore
hscore
hscore
limit
includ
heterogen
underli
diseas
high
proport
cancerassoci
hlh
retrospect
manner
data
collect
small
sampl
size
entir
studi
popul
valid
data
set
studi
includ
adult
reactiv
hlh
applic
children
particularli
sjiama
question
ad
limit
pediatr
case
criteria
hscore
might
practic
applic
children
exampl
definit
item
known
underli
immunosuppress
list
medic
use
infrequ
children
sjia
cyclosporin
azathioprin
time
mention
newer
wide
use
cytokin
antagonist
associ
occurr
ma
moreov
bone
marrow
aspir
search
hemophagocytosi
frequent
perform
children
sjiama
consid
mandatori
either
guidelin
preliminari
ma
guidelin
fact
absenc
hemophagocytosi
rule
ma
procedur
delay
appropri
therapi
furthermor
underli
inflammatori
natur
sjia
associ
mark
thrombocytosi
make
threshold
level
platelet
count
low
identifi
ma
set
sjia
rel
drop
platelet
count
rather
absolut
decreas
certain
threshold
use
make
earli
diagnosi
thu
hscore
like
valuabl
diagnos
adult
hlh
particularli
associ
leukemia
lymphoma
new
promis
laboratori
marker
ma
solubl
express
restrict
macrophagemonocyt
lineag
unlik
ferritin
solubl
receptor
produc
number
tissu
cell
type
includ
liver
spleen
heart
kidney
cell
varieti
nonspecif
inflammatori
condit
mainli
evalu
ma
combin
test
identifi
patient
subclin
ma
studi
evalu
role
hlh
associ
autoimmun
diseas
requir
moreov
like
test
current
avail
time
fashion
center
around
world
anoth
novel
biomark
follistatinrel
protein
report
gorelik
et
al
elev
activ
sjia
higher
level
ma
level
correl
ferritin
level
normal
treatment
perhap
importantli
gorelik
et
al
also
report
small
cohort
sjia
patient
ferritin
esr
ratio
highest
sensit
specif
respect
distinguish
ma
newonset
sjia
diseas
flare
ferritin
rise
due
inflamm
mashlh
esr
tend
drop
fibrinogen
import
driver
high
esr
consum
coagulopathi
simpl
ratio
ferritin
esr
may
prove
simpl
valuabl
tool
get
clinician
consid
diagnosi
mashlh
febril
hospit
patient
although
serum
level
also
routin
avail
clinic
may
also
serv
distinguish
biomark
sjia
patient
develop
ma
compar
cytokin
pattern
sjiama
patient
ebvhlh
kawasaki
diseas
healthi
agematch
control
shimizu
et
al
report
concentr
sjiama
significantli
higher
compar
other
correl
measur
diseas
activ
crp
ferritin
ldh
cytokin
addit
serum
neopterin
stnfrii
level
significantli
higher
ma
compar
sjia
flare
report
also
show
level
significantli
elev
sjia
patient
high
level
like
develop
ma
furthermor
sphingomyelinas
found
elev
hlh
case
thu
varieti
new
biomark
may
help
identifi
ma
among
sjia
patient
genet
hlh
commonli
classifi
two
group
fhlh
group
autosom
recess
disord
immunodefici
syndrom
relat
hlh
immunodefici
syndrom
chediakhigashi
griscelli
hermanskypudlak
associ
variabl
degre
albinismhypopigment
skin
hair
platelet
dysfunct
assist
identifi
potenti
case
hlh
tabl
interestingli
shlh
case
possess
heterozyg
mutat
fhlhassoci
gene
product
thu
overal
underli
genet
risk
shlh
may
rather
strike
addit
underli
inflammatori
state
eg
sjia
leukemia
genet
predisposit
eg
perforin
defici
infect
commens
human
microbiom
frequent
signific
contribut
factor
lower
threshold
requir
develop
cytokin
storm
syndrom
capabl
result
hlh
ma
tabl
hlh
associ
vast
varieti
infect
ebv
commonli
report
trigger
famili
fhlh
sporad
secondari
shlh
case
hlh
often
precipit
acut
infect
also
import
note
underli
precipit
infect
hlh
mask
hlh
clinic
pictur
mimic
infecti
process
mycoplasma
pneumonia
salmonella
typhi
staphylococcu
aureu
klebsiella
pneumonia
aeromona
hydrophila
fusobacterium
sp
chlamydia
pneumonia
legionella
pneumophila
mycobacterium
tuberculosi
mycobacterium
bovisweaken
form
bacillu
intraves
bcg
acinetobact
baumannii
escherichia
coli
lepra
abiotrophia
defectiva
endocard
patient
anaplasma
phagocytophilum
bartonella
hensela
borrelia
burgdorferi
lyme
diseas
brucella
sp
campylobact
sp
capnocytophaga
sp
clostridium
sp
coxiella
burnetii
ehrlichia
chaffeensi
ehrlichia
ewingii
leptospira
sp
listeria
monocytogen
mycobacterium
avium
complex
orientia
tsutsugamushi
rickettsia
spp
salmonella
sp
exclud
typhi
protozoalzoonot
protozoa
leishmania
sp
toxoplasma
gondii
babesia
sp
plasmodium
falciparum
plasmodium
vivax
strongyloid
stercorali
fungal
pneumocysti
jiroveci
candida
sp
aspergillu
sp
fusarium
verticillioid
cryptococcu
neoforman
histoplasma
capsulatum
penicillium
marneffei
overwhelm
septicemia
import
nonetheless
detect
remedi
underli
treatabl
infect
set
hlh
epidemiolog
previous
mention
ebv
commonli
report
trigger
hlh
highest
incid
east
asia
could
explain
pathogen
strain
ebv
part
world
also
higher
preval
ebv
ebvinfect
cell
asian
ebvassoci
hlh
ebvhlh
case
also
describ
usa
europ
ebvhlh
case
occur
appar
immunocompet
children
adolesc
howev
also
occur
set
primarygenet
form
fhlh
immunodefici
disord
eg
xlp
secondari
form
includ
acut
infect
eg
infecti
mononucleosi
lymphoprolif
disord
eg
nk
cell
tcell
leukemia
lymphoma
ebvhlh
infect
cell
ebv
result
cytokin
storm
releas
proinflammatori
cytokin
includ
tnf
lead
widespread
lymphohistiocyt
activ
result
cytokin
storm
tend
promin
observ
nonebvhlh
addit
impair
function
cell
nk
cell
thought
provid
phenotyp
present
hlh
result
ebv
via
genet
mutat
involv
tcell
andor
nk
cell
activ
pathway
diagnosi
serolog
test
help
differenti
primari
ebv
infect
reactiv
process
although
limit
delay
posit
difficulti
result
interpret
realtim
pcr
use
measur
ebv
viral
load
help
predict
prognosi
respons
treatment
ebv
pcr
level
usual
higher
seen
uncompl
case
ebv
infecti
mononucleosi
techniqu
avail
determin
involv
cell
nk
cell
help
confirm
diagnosi
tcell
receptor
tcr
gene
rearrang
detect
half
patient
ebvhlh
use
southern
blot
andor
pcr
analys
hypothes
presenc
chang
tcr
gene
clonal
probabl
play
prognost
role
ebvhlh
sandberg
et
al
recent
report
southern
blot
analysi
could
replac
multiplex
pcr
routin
test
tcell
clonal
euroclon
consortium
develop
uniform
report
system
descript
result
conclus
igtcr
clonal
assay
help
improv
gener
perform
level
clonal
assess
interpret
case
suspect
lymphoprolifer
report
tcr
gene
clonal
multiplex
pcr
highli
sensit
detect
tcell
clonal
use
predict
respons
treatment
ebvhlh
case
interestingli
found
male
patient
ebvhlh
may
mutat
gene
classic
associ
xlink
lymphoprolif
syndrom
xlp
xlp
syndrom
immunodefici
ebv
viru
therefor
recommend
test
xlp
male
patient
ebvhlh
also
recommend
test
genet
condit
fhlh
especi
male
patient
year
age
hlh
sibl
consanguin
parent
hlh
recurr
unrespons
treatment
prognosi
virus
associ
hlh
ebvhlh
carri
one
worst
prognos
nationwid
survey
japan
identifi
prognost
factor
children
ebvhlh
kogawa
et
al
found
clinic
laboratori
paramet
includ
ebv
load
nk
cell
activ
ebvinfect
cell
presenc
clonal
onset
diseas
associ
poor
outcom
nevertheless
matsuda
et
al
show
chang
clonal
good
marker
diseas
activ
childhood
ebvhlh
also
report
hyperbilirubinemia
hyperferritinemia
time
diagnosi
significantli
associ
poor
outcom
henter
et
al
also
report
hyperbilirubinemia
hyperferritinemia
diagnosi
thrombocytopenia
hyperferritinemia
week
initi
treatment
advers
affect
outcom
hlh
better
outcom
specul
associ
go
remiss
within
week
treatment
initi
huang
et
al
report
hypoalbuminemia
independ
predictor
hlh
childhood
ebvassoci
diseas
treatment
antivir
therapi
acyclovir
ganciclovir
cidofovir
gener
ineffect
monotherapi
infecti
mononucleosi
ebvhlh
howev
aggress
therapi
includ
immunochemotherapi
allogen
stem
cell
transplant
radic
improv
prognosi
optim
treatment
strategi
ebvhlh
consist
immunosuppress
medic
inhibit
overact
tcell
nk
cell
respons
ie
corticosteroid
cyclosporin
intraven
immunoglobulin
ivig
antithymocyt
globulin
etoposid
plasma
blood
exchang
transfus
hematopoiet
stem
cell
transplant
hsct
last
treatment
resort
refractori
form
ebvhlh
case
ebv
infect
occur
genet
form
hlh
despit
fact
report
shown
hsct
effect
treat
patient
refractori
ebvhlh
compar
immunochemotherapi
random
studi
provid
evid
approach
superior
andor
safer
balamuth
et
al
report
ad
rituximab
treatment
protocol
improv
efficaci
rituximab
monoclon
antibodi
surfac
b
cell
ebv
target
b
cell
initi
phase
diseas
rituximab
elimin
b
cell
thought
inhibit
extent
infect
addit
b
cell
may
target
ebvhlh
rituximab
may
reduc
morbid
mortal
reduc
circul
bcell
popul
ebv
load
rituximab
seem
effect
set
xlp
patient
infect
ebv
like
less
effect
ebv
capabl
infect
tcell
pool
nonetheless
addit
rituximab
treatment
repertoir
ebvhlh
provid
opportun
tailor
therapi
specif
patient
person
medicin
approach
follow
ebv
cytomegaloviru
cmv
human
herp
viru
hhv
next
common
herpesvirus
associ
hlh
cmv
infect
associ
hlh
otherwis
healthi
patient
prematur
infant
patient
inflammatori
bowel
diseas
rheumatolog
diseas
cancer
transplant
recipi
seri
patient
undergo
hsct
hlh
observ
trigger
cmv
case
japanes
registri
cmvhlh
diagnos
less
year
age
four
five
infant
die
suggest
younger
age
may
associ
wors
prognosi
use
specif
anticmv
therapi
cmv
hyperimmun
globulin
foscarnet
ganciclovir
associ
recoveri
select
case
associ
hlh
mostli
set
kaposi
sarcoma
multicentr
castleman
diseas
lymphoprolif
disord
well
immunocompromis
host
hiv
transplant
recipi
rare
immunocompet
host
prospect
cohort
patient
castleman
diseas
human
immunodefici
viru
hiv
hlh
intriguingli
seri
level
increas
though
cytokin
level
mani
known
inflammatori
marker
studi
patient
recov
treatment
splenectomi
etoposid
rituximab
ganciclovir
foscarnet
also
associ
recoveri
case
final
herp
virus
except
associ
hlh
due
lack
diseas
awar
among
mani
physician
hlh
present
within
first
week
life
rare
recogn
could
either
pass
undiagnos
diagnos
late
cours
even
autopsi
neonat
hlh
differ
hlh
older
children
etiolog
manifest
laboratori
find
nationwid
survey
japan
publish
neonat
diagnos
hlh
within
week
birth
diagnos
fhlh
diagnos
herp
simplex
virusassoci
hlh
hsvhlh
overal
surviv
rate
patient
fhlh
sever
combin
immunodefici
scid
hlh
hsvhlh
despit
acyclovir
treatment
although
uncommon
hlh
older
children
enteroviru
echoviru
coxsackieviru
hsv
associ
fatal
fulmin
neonat
hlh
mandat
earli
treatment
highdos
acyclovir
suspect
case
without
await
viral
studi
result
hlh
associ
hiv
infect
etiolog
acquir
immunodefici
syndrom
aid
differ
set
hlh
occur
either
hiv
alon
varieti
underli
associ
disord
hlh
report
acut
late
stage
hiv
infect
set
immun
reconstitut
inflammatori
syndrom
iri
associ
hivassoci
malign
infect
opportunist
nonopportunist
hlh
even
report
initi
present
hiv
infect
suggest
direct
role
hiv
trigger
hlh
due
fact
hiv
hlh
share
mani
similar
clinic
biolog
find
like
associ
also
underdiagnos
one
studi
hemophagocytosi
observ
autopsi
case
hivposit
patient
around
bone
marrow
biopsi
hiv
patient
highli
activ
antiretrovir
therapi
haart
initi
reveal
hemophagocytosi
adult
case
acut
hiv
infect
hlh
associ
low
tcell
count
almost
twothird
case
addit
lower
tcell
count
associ
wors
prognosi
associ
hlh
influenza
describ
season
avian
swine
nonpandem
influenza
also
associ
immunocompromis
otherwis
healthi
children
prospect
pediatr
studi
includ
children
hospit
season
influenza
one
case
fatal
outcom
interestingli
patient
sever
avian
influenza
clinic
pictur
laboratori
find
similar
hlh
consist
mainli
enceph
organ
dysfunct
hemophagocytosi
bone
marrow
suppress
cytokin
storm
common
characterist
patholog
pictur
seen
autopsi
biopsi
case
hemophagocytosi
clinic
studi
found
mutat
viral
gene
ha
na
significantli
relat
cytokin
releas
shown
recombin
hemagglutinin
viru
may
suppress
perforin
express
reduc
cytotox
cell
includ
abil
kill
cell
lead
mark
lymphoprolifer
hyperproduct
macrophag
overactiv
consid
high
mortal
caus
resist
mani
antivir
similar
hlh
sever
flu
infect
led
suggest
use
modifi
protocol
shorter
cours
etoposid
dexamethason
case
howev
random
studi
vietnam
patient
die
despit
receiv
corticosteroid
recent
studi
done
case
fatal
influenza
infect
met
modifi
ma
criteria
respect
five
subject
carri
one
three
differ
heterozyg
lyst
mutat
two
also
possess
rel
common
mutat
shown
mildli
decreas
nk
cell
cytolyt
function
sever
patient
also
carri
rare
variant
gene
previous
observ
patient
ma
high
percentag
hlh
gene
mutat
suggest
risk
factor
mortal
among
individu
influenza
infect
hlh
report
approxim
case
parvoviru
infect
hereditari
spherocytosi
underli
diseas
less
children
patient
surviv
receiv
treatment
suggest
better
prognosi
parvovirushlh
viral
infect
fulmin
viral
hepat
may
mimic
even
caus
hlh
hepat
viru
hav
frequent
associ
hlh
hepatotrop
virus
includ
hbv
hcv
fifteen
case
includ
children
describ
literatur
mainli
asia
three
patient
also
concurr
rheumatolog
diseas
sjia
relat
adult
onset
still
diseas
two
also
hepat
c
four
patient
surviv
without
specif
treatment
other
receiv
corticosteroid
without
ivig
overal
good
outcom
twelv
case
pediatr
enterovirusrel
hlh
describ
four
patient
underli
diseas
hodgkin
nonhodgkin
lymphoma
acut
lymphoblast
leukemia
jia
higher
mortal
rate
ten
patient
receiv
ivig
six
combin
corticosteroid
seven
patient
surviv
virus
associ
associ
hlh
tabl
vari
cours
corticosteroid
ivig
use
interestingli
hlh
may
contribut
high
mortal
rate
associ
certain
hemorrhag
fever
virus
caus
dengu
fever
ebola
bacteri
pathogen
intracellular
organ
commonli
precipit
bacteri
agent
hlh
pathophysiolog
probabl
relat
host
lymphocyt
monocyt
produc
high
level
activ
cytokin
defect
nk
cell
cytotox
tcell
function
also
hypothes
play
role
pathophysiolog
hlh
report
dissemin
mycobacterium
tuberculosi
tb
infect
occur
otherwis
healthi
patient
endstag
renal
diseas
patient
receiv
hemodialysi
undergon
renal
transplant
malign
hivaid
sarcoidosi
review
case
brastiano
et
al
case
evid
extrapulmonari
tuberculosi
mortal
rate
approxim
portray
poor
outcom
tbhlh
although
antitubercul
immunomodulatori
therapi
consist
highdos
corticosteroid
ivig
antithymocyt
globulin
cyclosporin
epipodophyllotoxin
plasma
exchang
may
lead
better
outcom
earli
diagnosi
time
administr
antitubercul
treatment
crucial
patient
moreov
one
report
case
hlh
occur
childhood
vaccin
bacillu
hlh
also
describ
associ
brucellosi
brucella
melitensi
frequent
isol
speci
leptospirosi
report
hlh
requir
treatment
corticosteroid
ivig
etoposid
addit
antibiot
treatment
report
also
relat
rickettsia
ehrlichia
hlh
prognosi
seem
influenc
specif
rickettsia
speci
patient
immunolog
statu
delay
antibiot
therapi
corticosteroid
therapi
also
ma
follow
urinari
tract
infect
acinetobact
baumannii
report
first
time
previous
healthi
child
recoveri
occur
without
cytotox
treatment
immunotherapi
use
multipl
dose
gcsf
red
blood
cellplatelet
transfus
like
virus
larg
array
addit
bacteri
infect
associ
hlh
tabl
propens
intracellular
invas
common
theme
mani
trigger
leishmania
infect
associ
hlh
particularli
leishmania
donovani
leishmania
infantum
consid
present
organomegali
pancytopenia
also
mimic
syndrom
hlh
import
nonendem
area
viscer
leishmaniasi
unlik
consid
differenti
diagnosi
repeat
bone
marrow
smear
often
requir
identifi
leishmania
speci
mean
pcr
speciesspecif
probe
specif
treatment
amphotericin
b
usual
suffici
control
hlh
fatal
outcom
seen
undiagnos
leishmania
case
treat
hlh
histori
travel
endem
area
also
utmost
import
suspect
hlh
secondari
certain
parasit
infect
malaria
toxoplasma
babesia
strongyloid
yeast
infect
candida
sp
cryptococcu
sp
pneumocysti
sp
mold
histoplasma
sp
aspergillu
sp
fusarium
sp
associ
hlh
commonli
hiv
infect
malign
prolong
corticosteroid
administr
transplant
dissemin
penicillium
marneffei
infect
common
among
hivinfect
patient
southeast
asia
first
case
penicilliosishlh
report
thai
hivinfect
child
complet
recoveri
antifung
ivig
therapi
addit
treat
underli
infect
treatment
design
dampen
cytokin
storm
associ
mashlh
critic
improv
surviv
tabl
research
report
success
highdos
corticosteroid
alon
treat
sjiama
fundament
role
corticosteroid
therapi
diseas
doubt
current
regimen
usual
add
aggress
treatment
corticosteroid
includ
cyclophosphamid
gain
wide
use
condit
cyclosporin
csa
current
commonli
ad
medicin
corticosteroid
etoposidebas
regimen
insignific
mortal
rate
preand
postbon
marrow
transplant
period
biolog
ivig
use
particularli
infectionassoci
shlh
ivig
must
given
earli
diseas
effect
furthermor
ivig
shown
ineffect
report
antithymocyt
globulin
use
success
two
patient
probabl
ma
carri
signific
risk
seriou
infect
mortal
recent
newer
target
biolog
therapi
provid
target
effect
option
treat
sjiama
initi
excit
tnf
blocker
report
success
treat
mani
case
ma
includ
sever
children
sjia
report
tnf
inhibitor
trigger
ma
diminish
enthusiasm
therapi
know
caus
effect
certainli
difficult
prove
situat
fact
ma
develop
set
tnf
inhibit
concern
led
focus
therapi
direct
two
proinflammatori
cytokin
receptor
antagonist
anakinra
shown
highli
effect
sjia
ma
sjia
flare
share
mani
clinic
laboratori
featur
moreov
addit
risk
develop
overt
ma
part
sjia
anoth
sjia
patient
may
occult
subclin
ma
flare
eventu
lead
overt
ma
suggest
anakinra
would
also
valuabl
treatment
sjiama
sever
report
dramat
success
use
anakinra
case
sjiama
fail
respond
corticosteroid
csa
anakinra
regard
gener
safe
drug
recombin
human
protein
short
halflif
approxim
h
wide
therapeut
window
mgkgday
howev
case
hepat
attribut
anakinra
children
sjia
report
moreov
though
caus
effect
difficult
establish
suggest
anakinra
trigger
ma
two
children
sjia
larg
case
seri
sjia
patient
treat
anakinra
diseas
onset
anakinra
potenti
ma
trigger
five
children
dose
mgkgday
howev
dose
escal
anakinra
often
seem
help
control
ma
none
children
perman
stop
anakinra
research
need
defin
role
anakinra
sjiama
form
shlh
blockad
via
receptor
monoclon
antibodi
tocilizumab
also
proven
success
treat
sjia
howev
case
report
ma
attribut
blockad
underscor
need
studi
defin
role
treatment
sjiama
blockad
howev
success
use
treat
cytokin
storm
syndrom
associ
chimer
antigen
receptor
car
tcelldirect
therapi
resist
leukemia
biolog
therapi
explor
costimulatori
blockad
cytotox
tlymphocyteassoci
protein
anecdot
benefici
children
sever
sjia
role
treat
ma
unknown
nevertheless
build
evid
biolog
therapi
particularli
inhibitor
welcom
addit
corticosteroid
csa
treat
ma
associ
sjia
final
rituximab
recent
report
lead
remiss
sizabl
percentag
children
refractori
sjia
addit
effect
treat
ebvhlh
first
report
success
hsct
hlh
report
hsct
tend
frequent
use
famili
case
hlh
use
secondari
case
well
sever
studi
shown
hsct
best
option
perman
diseas
control
cure
overal
transplant
morbid
mortal
still
high
uncommon
patient
develop
recurr
hlh
suitabl
donor
identifi
moreov
autolog
allogen
hsct
report
induc
hlh
transplant
patient
probabl
due
increas
risk
infect
impos
immunosuppress
condit
regimen
estim
risk
recent
cohort
risk
appear
reduc
etoposidecontain
condit
regimen
current
era
biolog
therapi
reduc
need
hsct
futur
autolog
hsct
combin
gene
therapi
correct
genet
defect
might
applic
carmo
et
al
shown
transfer
function
perforin
gene
autolog
hematopoiet
stem
cell
perforindefici
mice
restor
perforin
express
partial
repair
cytotox
defect
attenu
hlh
symptom
viral
challeng
provid
least
engraft
attain
similarli
rivat
et
al
show
mous
model
xlp
gene
transfer
also
restor
sap
express
normal
cytotox
function
shown
play
pivot
role
sever
hlh
model
neutral
substanti
improv
surviv
hlh
anim
model
ma
model
use
transgen
mice
level
induc
chemokin
elev
children
hlh
moreov
sjiama
commonli
trigger
viral
infect
known
activ
pathway
furthermor
numer
cell
found
close
proxim
activ
hemophagocyt
histiocyt
studi
inflammatori
infiltr
tissu
affect
ma
children
ma
show
increas
level
neopterin
known
releas
interferonstimul
macrophag
longitudin
studi
cytokin
chang
patient
sjia
show
level
chemokin
particularli
markedli
increas
begin
clinic
ma
return
normal
resolut
furthermor
strongli
correl
mani
laboratori
featur
associ
ma
find
highlight
appeal
target
potenti
less
toxic
therapeut
option
hlh
clinic
trial
evalu
monoclon
antibodi
bind
neutral
human
underway
recent
report
trial
show
promis
result
howev
recent
studi
question
potenti
block
therapi
ma
first
tesi
et
al
report
two
case
hlh
children
novel
receptor
mutat
associ
defici
find
highlight
signific
mechan
immun
patholog
hlh
warrant
novel
therapi
besid
therapi
investig
addit
sjia
patient
found
normal
level
independ
diseas
activ
suggest
cytokin
alway
play
essenti
role
diseas
pathogenesi
target
individu
cytokin
might
insuffici
sever
hypercytokinemia
cytokin
signal
pathway
target
avoid
imbal
cytokin
network
janu
kinas
control
signal
mani
cytokin
notabl
thu
inhibit
janu
kinas
via
ruxolitinib
exampl
may
serv
purpos
da
et
al
report
rodent
model
primari
secondari
hlh
treatment
inhibitor
ruxolitinib
significantli
lessen
clinic
laboratori
manifest
includ
weight
loss
organomegali
anemia
thrombocytopenia
hypercytokinemia
tissu
inflamm
importantli
ruxolitinib
treatment
also
significantli
improv
surviv
model
similarli
maschalidi
et
al
report
inhibit
mice
fullblown
hlh
syndrom
led
recoveri
model
peroxisom
proliferatoractiv
agonist
also
present
potenti
agent
interfer
activ
pathway
exert
broad
antiinflammatori
effect
antivir
capac
base
research
hlh
anim
model
target
futur
therapi
propos
includ
induct
tcell
exhaust
stimul
inhibitori
receptor
like
program
cell
death
restor
cytokin
balanc
antiinflammatori
halt
chronic
tlr
activ
tlr
antagonist
block
tlr
signal
pathway
target
dendrit
cell
main
driver
ongo
antigen
stimul
suppress
antigen
present
past
year
reveal
role
pathogenesi
sjia
ma
shown
patient
sjia
significantli
higher
level
oppos
rheumat
diseas
sle
rheumatoid
arthriti
sjia
patient
high
level
like
develop
system
featur
diseas
prone
develop
ma
interestingli
develop
ma
patient
associ
rise
level
also
found
correl
ferritin
adult
onset
still
diseas
therefor
suggest
promis
biomark
ma
anoth
interest
field
grow
research
role
protein
natur
occur
protein
counterregul
activ
imbal
lead
higher
level
unbound
found
patient
increas
diseas
sever
administr
synthet
perforindefici
mice
infect
murin
cmv
amelior
liver
damag
shown
effect
proinflammatori
cytokin
level
overal
surviv
base
find
work
need
demonstr
role
ma
along
line
shown
benefici
treat
refractori
ma
child
mutat
recent
neutral
antibodi
antagonist
target
alarmin
high
mobil
group
box
propos
potenti
therapeut
option
aim
reduc
immunostimulatori
load
necrosisand
pyroptosisderiv
danger
signal
model
system
steril
infecti
inflamm
demonstr
efficaci
strategi
moreov
block
alarmin
via
receptor
also
potenti
therapi
overal
futur
look
brighter
varieti
potenti
therapeut
treat
hlhma
patientspecif
fashion
